Anti-Angiogenic Therapy in the Treatment of Non-Small Cell Lung Cancer

Overview

Journal Onco Targets Ther

Publisher Dove Medical Press

Specialty Oncology

Date 2020 Dec 2

PMID 33262610

Citations 22

Authors

Wentao Tian

Chenghui Cao

Long Shu

Fang Wu

Affiliations

Soon will be listed here.

Abstract

Angiogenesis plays an essential role in the development of most solid tumors by delivering nutrients and oxygen to the tumor. Therefore, anti-angiogenic therapy, particularly anti-VEGF and anti-VEGF receptor (VEGFR) therapy, has been a popular strategy to treat cancer. However, anti-angiogenic therapy does not significantly improve patients' outcomes when used alone because the cutdown of the vessels transforms tumor cells to a hypoxia-tolerant phenotype. While combining anti-angiogenic therapy with other therapies, including chemotherapy, radiotherapy, immunotherapy, and anti-epidermal growth factor receptor (EGFR) therapy, has a promising efficacy due to the vessel normalization effect induced by anti-angiogenic agents. Here, we review the characteristics of tumor angiogenesis, the mechanisms, clinical applications, and prospects of combining anti-angiogenic therapy with other therapies in the treatment of non-small cell lung cancer.

Citing Articles

Hypoxia studies in non‑small cell lung cancer: Pathogenesis and clinical implications (Review).

Zhou S, Sun J, Zhu W, Yang Z, Wang P, Zeng Y Oncol Rep. 2025; 53(2.

PMID: 39749693 PMC: 11715622. DOI: 10.3892/or.2024.8862.

Bioinformatics Identification of angiogenesis-related biomarkers and therapeutic targets in cerebral ischemia-reperfusion.

Wu Y, Sun J, Huang J, Lu X Sci Rep. 2024; 14(1):32096.

PMID: 39738531 PMC: 11685884. DOI: 10.1038/s41598-024-83783-9.

Anti‑angiogenic effect of ‑derived peptide via aquaporin 3 in non‑small cell lung cancer.

Kim H, Jung S, Jo S, Han J, Yoon M, Lee J Int J Oncol. 2024; 66(1).

PMID: 39611488 PMC: 11637497. DOI: 10.3892/ijo.2024.5711.

Cancer stem cells: advances in knowledge and implications for cancer therapy.

Chu X, Tian W, Ning J, Xiao G, Zhou Y, Wang Z Signal Transduct Target Ther. 2024; 9(1):170.

PMID: 38965243 PMC: 11224386. DOI: 10.1038/s41392-024-01851-y.

Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer.

Wang L, Du C, Jiang B, Chen L, Wang Z Front Immunol. 2023; 14:1256740.

PMID: 37901223 PMC: 10600379. DOI: 10.3389/fimmu.2023.1256740.

References

Han B, Li K, Wang Q, Zhang L, Shi J, Wang Z . Effect of Anlotinib as a Third-Line or Further Treatment on Overall Survival of Patients With Advanced Non-Small Cell Lung Cancer: The ALTER 0303 Phase 3 Randomized Clinical Trial. JAMA Oncol. 2018; 4(11):1569-1575. PMC: 6248083. DOI: 10.1001/jamaoncol.2018.3039. View

Johnson B, Kabbinavar F, Fehrenbacher L, Hainsworth J, Kasubhai S, Kressel B . ATLAS: randomized, double-blind, placebo-controlled, phase IIIB trial comparing bevacizumab therapy with or without erlotinib, after completion of chemotherapy, with bevacizumab for first-line treatment of advanced non-small-cell lung cancer. J Clin Oncol. 2013; 31(31):3926-34. DOI: 10.1200/JCO.2012.47.3983. View

Wang S, Yang Z, Wang Z . Are VEGFR-TKIs effective or safe for patients with advanced non-small cell lung cancer?. Oncotarget. 2015; 6(20):18206-23. PMC: 4627246. DOI: 10.18632/oncotarget.4524. View

Li L, Zhao W, Sun X, Liu N, Zhou Y, Luan X . F-RGD PET/CT imaging reveals characteristics of angiogenesis in non-small cell lung cancer. Transl Lung Cancer Res. 2020; 9(4):1324-1332. PMC: 7481644. DOI: 10.21037/tlcr-20-187. View

Socinski M, Jotte R, Cappuzzo F, Orlandi F, Stroyakovskiy D, Nogami N . Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC. N Engl J Med. 2018; 378(24):2288-2301. DOI: 10.1056/NEJMoa1716948. View

Reinmuth N, Jauch A, Xu E, Muley T, Granzow M, Hoffmann H . Correlation of EGFR mutations with chromosomal alterations and expression of EGFR, ErbB3 and VEGF in tumor samples of lung adenocarcinoma patients. Lung Cancer. 2008; 62(2):193-201. DOI: 10.1016/j.lungcan.2008.03.011. View

Hellmann M, Rizvi N, Goldman J, Gettinger S, Borghaei H, Brahmer J . Nivolumab plus ipilimumab as first-line treatment for advanced non-small-cell lung cancer (CheckMate 012): results of an open-label, phase 1, multicohort study. Lancet Oncol. 2016; 18(1):31-41. PMC: 5476941. DOI: 10.1016/S1470-2045(16)30624-6. View

Akkermans R . Third-generation EGFR-TKIs—a new hope for NSCLC. Lancet Respir Med. 2014; 2(7):520. DOI: 10.1016/s2213-2600(14)70095-5. View

Zhou C, Wu Y, Chen G, Liu X, Zhu Y, Lu S . BEYOND: A Randomized, Double-Blind, Placebo-Controlled, Multicenter, Phase III Study of First-Line Carboplatin/Paclitaxel Plus Bevacizumab or Placebo in Chinese Patients With Advanced or Recurrent Nonsquamous Non-Small-Cell Lung Cancer. J Clin Oncol. 2015; 33(19):2197-204. DOI: 10.1200/JCO.2014.59.4424. View

10.

Teng M, Ngiow S, Ribas A, Smyth M . Classifying Cancers Based on T-cell Infiltration and PD-L1. Cancer Res. 2015; 75(11):2139-45. PMC: 4452411. DOI: 10.1158/0008-5472.CAN-15-0255. View

11.

Sandler A, Gray R, Perry M, Brahmer J, Schiller J, Dowlati A . Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer. N Engl J Med. 2006; 355(24):2542-50. DOI: 10.1056/NEJMoa061884. View

12.

Herbst R, Sun Y, Eberhardt W, Germonpre P, Saijo N, Zhou C . Vandetanib plus docetaxel versus docetaxel as second-line treatment for patients with advanced non-small-cell lung cancer (ZODIAC): a double-blind, randomised, phase 3 trial. Lancet Oncol. 2010; 11(7):619-26. PMC: 3225192. DOI: 10.1016/S1470-2045(10)70132-7. View

13.

Kato T, Seto T, Nishio M, Goto K, Yamamoto N, Okamoto I . Erlotinib Plus Bevacizumab Phase ll Study in Patients with Advanced Non-small-Cell Lung Cancer (JO25567): Updated Safety Results. Drug Saf. 2017; 41(2):229-237. PMC: 5808045. DOI: 10.1007/s40264-017-0596-0. View

14.

Claesson-Welsh L, Welsh M . VEGFA and tumour angiogenesis. J Intern Med. 2012; 273(2):114-27. DOI: 10.1111/joim.12019. View

15.

Jiang X, Ding M, Qiao Y, Liu Y, Liu L . Recombinant human endostatin combined with radiotherapy in the treatment of brain metastases of non-small cell lung cancer. Clin Transl Oncol. 2013; 16(7):630-6. DOI: 10.1007/s12094-013-1129-7. View

16.

Jain R . Normalizing tumor microenvironment to treat cancer: bench to bedside to biomarkers. J Clin Oncol. 2013; 31(17):2205-18. PMC: 3731977. DOI: 10.1200/JCO.2012.46.3653. View

17.

Viallard C, Larrivee B . Tumor angiogenesis and vascular normalization: alternative therapeutic targets. Angiogenesis. 2017; 20(4):409-426. DOI: 10.1007/s10456-017-9562-9. View

18.

Rey S, Schito L, Wouters B, Eliasof S, Kerbel R . Targeting Hypoxia-Inducible Factors for Antiangiogenic Cancer Therapy. Trends Cancer. 2017; 3(7):529-541. DOI: 10.1016/j.trecan.2017.05.002. View

19.

Gentzler R, Yentz S, Patel J . Bevacizumab in advanced NSCLC: chemotherapy partners and duration of use. Curr Treat Options Oncol. 2013; 14(4):595-609. DOI: 10.1007/s11864-013-0255-3. View

20.

Coelho A, Gomes M, Catarino R, Rolfo C, Lopes A, Medeiros R . Angiogenesis in NSCLC: is vessel co-option the trunk that sustains the branches?. Oncotarget. 2016; 8(24):39795-39804. PMC: 5503654. DOI: 10.18632/oncotarget.7794. View